The best evidence bearing on immune surveillance comes from studies on the incidence of tumours in human transplant recipients . The most recent U.K./Australasian figures for relative risk (and no. of cases) are as follows: non-Hodgkins lymphoma, 49 (42); skin, 9 (24); melanoma, 9 (2); all others, 1.4 (94). Some and perhaps all of this is indicative of viral oncogenesis. The best animal data concern tumour-specific transplantation antigens (TSTA) in chemically induced  and UV-induced  cancer.
KeywordsEpstein Barr Virus Immune Surveillance Transferrin Receptor Major Effector Tumour Immunology
- 1.Mitchison, N.A., Kinlen, L. (1980) in Immunology ‘80 [4th Int. Congr. Inmunol., Paris, July 1980] (Fougereau, M. and Dausset, J.), Academic Press, London, pp. 641–650.Google Scholar